https://nl.marketscreener.com/koers/aandeel/MERCK-CO-INC-13611/nieuws/Europese-Commissie-keurt-Keytruda-Pembrolizumab-plus-chemotherapie-van-Merck-goed-46310983/?utm_source=telegram&utm_medium=social&utm_campaign=share